|
Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma. |
|
|
Travel, Accommodations, Expenses - GlaxoSmithKline |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche Pharma AG |
Research Funding - Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - NanoString Technologies |
|
|
No Relationships to Disclose |